NA
CTXR icon

NewEdge Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

NewEdge Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360 Hold
400
– – ﹤0.01% 4021
2025
Q4 		$311 Sell
400
-25,000
-98% -$31.3K ﹤0.01% 4109
2025
Q3 		$31.5K Buy
25,400
+400
+2% +$558 ﹤0.01% 2980
2025
Q2 		$39.8K Buy
+25,000
New +$22.9K ﹤0.01% 2735

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NewEdge Advisors's CTXR Position: Q1 2026 in Review

NewEdge Advisors held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 400 shares worth $360. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

NewEdge Advisors first reported a position in CTXR in Q2 2025 and has held it in 4 quarters since. The position peaked at $39.8K in Q2 2025. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • NewEdge Advisors held 400 shares of Citius Pharmaceuticals worth $360 as of Q1 2026.
  • NewEdge Advisors left its Citius Pharmaceuticals share count unchanged in Q1 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4021 holding.
  • NewEdge Advisors first reported a position in Citius Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • NewEdge Advisors's Citius Pharmaceuticals position peaked at $39.8K in Q2 2025.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.